{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:14:49Z","timestamp":1791832489746,"version":"4.3.4"},"reference-count":108,"publisher":"Elsevier BV","issue":"49","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"Wellcome Trust and European Union","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.vaccine.2020.08.031","type":"journal-article","created":{"date-parts":[[2020,8,30]],"date-time":"2020-08-30T13:43:35Z","timestamp":1598795015000},"page":"7716-7727","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Broad vaccine protection against Neisseria meningitidis using factor H binding protein"],"prefix":"10.1016","volume":"38","author":[{"given":"Jamie","family":"Findlow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Bayliss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter T.","family":"Beernink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Liberator","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Balmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.08.031_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2019.103571","article-title":"Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: a systematic review and meta-analysis","volume":"134","author":"Purmohamad","year":"2019","journal-title":"Microb Pathog"},{"key":"10.1016\/j.vaccine.2020.08.031_b0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/14760584.2019.1557520","article-title":"The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations","volume":"18","author":"Acevedo","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2020.08.031_b0015","unstructured":"European Centre for Disease Prevention and Control. Annual epidemiological report for 2017: invasive meningococcal disease; 2019 [accessed July 17, 2019]. https:\/\/ecdc.europa.eu\/sites\/portal\/files\/documents\/AER_for_2017-invasive-meningococcal-disease.pdf."},{"key":"10.1016\/j.vaccine.2020.08.031_b0020","unstructured":"Centers for Disease Control. Enhanced meningococcal disease surveillance report, 2017; 2017 [accessed May 10, 2019]. https:\/\/www.cdc.gov\/meningococcal\/downloads\/NCIRD-EMS-Report-2017.pdf."},{"key":"10.1016\/j.vaccine.2020.08.031_b0025","unstructured":"Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR Recomm Rep, https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/rr6202a1.htm; 2013 [accessed February 3, 2020]."},{"key":"10.1016\/j.vaccine.2020.08.031_b0030","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMra0906357","article-title":"Advances in the development of vaccines against Neisseria meningitidis","volume":"362","author":"Tan","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.08.031_b0035","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/infdis\/126.5.514","article-title":"Immunologic response of man to group B meningococcal polysaccharide vaccines","volume":"126","author":"Wyle","year":"1972","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.08.031_b0040","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis","volume":"2","author":"Finne","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2020.08.031_b0045","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4161\/hv.34293","article-title":"The discovery and development of a novel vaccine to protect against Neisseria meningitidis serogroup B disease","volume":"11","author":"Zlotnick","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.08.031_b0050","unstructured":"PubMLST. Neisseria sequence typing home page, University of Oxford; 2019 [accessed December 16, 2019]. http:\/\/pubmlst.org\/neisseria\/."},{"key":"10.1016\/j.vaccine.2020.08.031_b0055","unstructured":"Bexsero\u00ae, GSK Vaccines, Srl; 2018 [accessed July 7, 2020]. https:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm431447.pdf."},{"key":"10.1016\/j.vaccine.2020.08.031_b0060","unstructured":"Trumenba\u00ae (meningococcal group B vaccine); 2017 [accessed February 28, 2018]. https:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm421139.pdf."},{"key":"10.1016\/j.vaccine.2020.08.031_b0065","unstructured":"GlaxoSmithKline Brasil Ltda. Modelo de texto de bula \u2013 Profissional de Sa\u00fade: BexseroTM, 2019 [accessed November 1, 2019]. https:\/\/br.gsk.com\/media\/613334\/l1310_bexsero_susp_inj_gds010.pdf."},{"key":"10.1016\/j.vaccine.2020.08.031_b0070","unstructured":"European Medicines Agency. Annex I: Summary of product characteristics (Bexsero) [accessed November 7, 2018]. https:\/\/www.ema.europa.eu\/documents\/product-information\/bexsero-epar-product-information_en.pdf."},{"key":"10.1016\/j.vaccine.2020.08.031_b0075","unstructured":"Ministerio de Salud (Uruguay). Vacunas antimeningoc\u00f3cicas en Uruguay [accessed November 1, 2019]. https:\/\/www.gub.uy\/ministerio-salud-publica\/sites\/ministerio-salud-publica\/files\/documentos\/noticias\/Postura%20sobre%20vacunas%20antimeningoc\u00f3cicas%20en%20Uruguay%202310.pdf."},{"key":"10.1016\/j.vaccine.2020.08.031_b0080","unstructured":"GlaxoSmithKline (Israel) Ltd. Bexsero; 2017 [accessed November 1, 2019]. https:\/\/www.old.health.gov.il\/units\/pharmacy\/trufot\/alonim\/Rishum_7_64465718.pdf."},{"key":"10.1016\/j.vaccine.2020.08.031_b0085","unstructured":"Sociedad Argentina de Pediatria. Lo que el pediatra debe saber sobre vacuna para Neisseria meningitis B(4CMenB) \u00aeBexsero; [accessed November 1, 2019]. https:\/\/www.sap.org.ar\/novedades\/194\/lo-que-el-pediatra-debe-saber-sobre-vacuna-para-neisseria-meningitis-b4cmenb-bexsero-.html."},{"key":"10.1016\/j.vaccine.2020.08.031_b0090","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1097\/INF.0b013e318199f61b","article-title":"Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV)","volume":"28","author":"Knuf","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2020.08.031_b0095","unstructured":"GlaxoSmithKline Australia Pty Ltd. Australian product information: Bexsero (multicomponent meningococcal group B vaccine) suspension for injection; 2018 [accessed November 1, 2019]. https:\/\/au.gsk.com\/media\/404836\/bexsero_pi_007.pdf."},{"key":"10.1016\/j.vaccine.2020.08.031_b0100","unstructured":"Product Monograph: Bexsero, GlaxoSmithKline Inc; 2017 [accessed February 14, 2018]. https:\/\/ca.gsk.com\/media\/1212390\/bexsero.pdf."},{"key":"10.1016\/j.vaccine.2020.08.031_b0105","unstructured":"New Zealand Data Sheet (Bexsero), 2018 [accessed November 1, 2019]. https:\/\/www.medsafe.govt.nz\/profs\/Datasheet\/b\/bexseroinj.pdf"},{"key":"10.1016\/j.vaccine.2020.08.031_b0110","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1128\/IAI.72.4.2088-2100.2004","article-title":"Vaccine potential of the Neisseria meningitidis 2086 lipoprotein","volume":"72","author":"Fletcher","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.08.031_b0115","unstructured":"European Medicines Agency. Annex I: Summary of product characteristics (Trumenba) [accessed November 7, 2018] https:\/\/www.ema.europa.eu\/documents\/product-information\/trumenba-epar-product-information_en.pdf."},{"key":"10.1016\/j.vaccine.2020.08.031_b0120","unstructured":"Pfizer Canada Inc. Product monograph: Trumenba, Pfizer Canada Inc, 2017 [accessed October 11, 2018] https:\/\/pdf.hres.ca\/dpd_pm\/00041515.PDF."},{"key":"10.1016\/j.vaccine.2020.08.031_b0125","unstructured":"Australian Government Department of Health. Product Information: Trumenba\u00ae, 2019 [accessed July 18, 2019] https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2017-PI-02674-1."},{"key":"10.1016\/j.vaccine.2020.08.031_b0130","unstructured":"Folleto de informaci\u00f3n al profesional Trumenba suspensi\u00f3n inyectable (vacuna meningoc\u00f3cica recombinante, adsorbida (grupo B)), [accessed November 1, 2019] https:\/\/docplayer.es\/90688351-Folleto-de-informacion-al-profesional-trumenba-suspension-inyectable-vacuna-meningococica-recombinante-adsorbida-grupo-b.html."},{"key":"10.1016\/j.vaccine.2020.08.031_b0135","doi-asserted-by":"crossref","unstructured":"Rossi R, Beernink PT, Giuntini S, Granoff DM. Susceptibility of meningococcal strains responsible for two serogroup B outbreaks on U.S. university campuses to serum bactericidal activity elicited by the MenB-4C vaccine. Clin Vaccine Immunol 2015;22:1227-34.","DOI":"10.1128\/CVI.00474-15"},{"key":"10.1016\/j.vaccine.2020.08.031_b0140","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1128\/jb.169.6.2781-2792.1987","article-title":"Genetic structure of Neisseria meningitidis populations in relation to serogroup, serotype, and outer membrane protein pattern","volume":"169","author":"Caugant","year":"1987","journal-title":"J Bacteriol"},{"key":"10.1016\/j.vaccine.2020.08.031_b0145","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/21645515.2017.1264750","article-title":"Meningococcal serogroup B vaccines: estimating breadth of coverage","volume":"13","author":"Donald","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.08.031_b0150","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/1040841X.2017.1329276","article-title":"The next chapter for group B meningococcal vaccines","volume":"44","author":"Wang","year":"2018","journal-title":"Crit Rev Microbiol"},{"key":"10.1016\/j.vaccine.2020.08.031_b0155","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/0140-6736(91)91961-S","article-title":"Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway","volume":"338","author":"Bjune","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2020.08.031_b0160","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1128\/JCM.01653-09","article-title":"Clonal distribution of disease-associated and healthy carrier isolates of Neisseria meningitidis between 1983 and 2005 in Cuba","volume":"48","author":"Climent","year":"2010","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2020.08.031_b0165","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1016\/j.vaccine.2011.06.120","article-title":"Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand","volume":"29","author":"Arnold","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.08.031_b0170","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1128\/CVI.00230-06","article-title":"Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents","volume":"14","author":"Boutriau","year":"2007","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2020.08.031_b0175","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1128\/IAI.71.4.1650-1655.2003","article-title":"Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine","volume":"71","author":"Vermont","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.08.031_b0180","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.vaccine.2012.12.031","article-title":"Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease","volume":"31","author":"Kaaijk","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.08.031_b0185","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1084\/jem.20021911","article-title":"Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870","volume":"197","author":"Masignani","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2020.08.031_b0190","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1128\/MMBR.00056-12","article-title":"The role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease","volume":"77","author":"McNeil","year":"2013","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.vaccine.2020.08.031_b0195","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1086\/600141","article-title":"Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis","volume":"200","author":"Murphy","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.08.031_b0200","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.3389\/fmicb.2019.02847","article-title":"Variant signal peptides of vaccine antigen, FHbp, impair processing affecting surface localization and antibody-mediated killing in most meningococcal isolates","volume":"10","author":"da Silva","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2020.08.031_b0205","doi-asserted-by":"crossref","first-page":"7566","DOI":"10.4049\/jimmunol.176.12.7566","article-title":"Functional significance of factor H binding to Neisseria meningitidis","volume":"176","author":"Schneider","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2020.08.031_b0210","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1128\/IAI.01191-08","article-title":"Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera","volume":"77","author":"Granoff","year":"2009","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.08.031_b0215","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1128\/IAI.01071-08","article-title":"Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37","volume":"77","author":"Seib","year":"2009","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.08.031_b0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001027","article-title":"The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement","volume":"6","author":"Lewis","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2020.08.031_b0225","doi-asserted-by":"crossref","unstructured":"Lewis LA, Vu DM, Vasudhev S, Shaughnessy J, Granoff DM, Ram S. Factor H-dependent alternative pathway inhibition mediated by porin B contributes to virulence of Neisseria meningitidis. mBio 2013;4:e00339-13. https:\/\/dx.doi.org\/10.1128\/mBio.00339-13.","DOI":"10.1128\/mBio.00339-13"},{"key":"10.1016\/j.vaccine.2020.08.031_b0230","doi-asserted-by":"crossref","unstructured":"Madico G, Welsch JA, Lewis LA, McNaughton A, Perlman DH, Costello CE, et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 2006;177:501-10.","DOI":"10.4049\/jimmunol.177.1.501"},{"key":"10.1016\/j.vaccine.2020.08.031_b0235","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1128\/CVI.00055-11","article-title":"Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein","volume":"18","author":"Lucidarme","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2020.08.031_b0240","first-page":"95","volume":"75","author":"Lucidarme","year":"2017","journal-title":"Frequent capsule switching in 'ultra-virulent' meningococci - Are we ready for a serogroup B ST-11 complex outbreak? J Infect"},{"key":"10.1016\/j.vaccine.2020.08.031_b0245","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1016\/j.vaccine.2010.06.083","article-title":"Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease","volume":"28","author":"Jiang","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.08.031_b0250","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1128\/IAI.02984-14","article-title":"Binding of complement factor H to PorB3 and NspA enhances resistance of Neisseria meningitidis to anti-factor H binding protein bactericidal activity","volume":"83","author":"Giuntini","year":"2015","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.08.031_b0255","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1073\/pnas.0603940103","article-title":"A universal vaccine for serogroup B meningococcus","volume":"103","author":"Giuliani","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2020.08.031_b0260","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy","volume":"51","author":"Findlow","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2020.08.031_b0265","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1097\/INF.0b013e3181f59f6d","article-title":"Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial","volume":"29","author":"Snape","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2020.08.031_b0270","doi-asserted-by":"crossref","first-page":"646","DOI":"10.4161\/hv.7.6.15482","article-title":"The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans","volume":"7","author":"Toneatto","year":"2011","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2020.08.031_b0275","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1086\/589308","article-title":"Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin","volume":"198","author":"Koeberling","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.08.031_b0280","doi-asserted-by":"crossref","unstructured":"Rajam G, Stella M, Kim E, Paulos S, Boccadifuoco G, Serino L, et al. Meningococcal antigen typing system (MATS)-based Neisseria meningitidis serogroup B coverage prediction for the MenB-4C vaccine in the United States. mSphere 2017;2. https:\/\/doi.org\/10.1128\/mSphere.00261-17.","DOI":"10.1128\/mSphere.00261-17"},{"key":"10.1016\/j.vaccine.2020.08.031_b0285","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","article-title":"Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment","volume":"13","author":"Vogel","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2020.08.031_b0290","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3389\/fimmu.2019.00751","article-title":"The development of a vaccine against meningococcus B using reverse vaccinology","volume":"10","author":"Masignani","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2020.08.031_b0295","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1016\/j.vaccine.2010.05.014","article-title":"Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus","volume":"28","author":"Giuliani","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.08.031_b0300","doi-asserted-by":"crossref","unstructured":"Brunelli B, Del Tordello E, Palumbo E, Biolchi A, Bambini S, Comanducci M, et al. Influence of sequence variability on bactericidal activity sera induced by factor H binding protein variant 1.1. Vaccine 2011;29:1072-81. https:\/\/dx.doi.org\/10.1016\/j.vaccine.2010.11.064.","DOI":"10.1016\/j.vaccine.2010.11.064"},{"key":"10.1016\/j.vaccine.2020.08.031_b0305","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/infdis\/jit239","article-title":"Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines","volume":"208","author":"Konar","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.08.031_b0310","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.vaccine.2012.12.022","article-title":"Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?","volume":"31","author":"Hong","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.08.031_b0315","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1128\/CVI.00825-13","article-title":"Neisseria adhesin A variation and revised nomenclature scheme","volume":"21","author":"Bambini","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2020.08.031_b0320","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1901229","article-title":"Vaccination of infants with meningococcal group B vaccine (4CMenB) in England","volume":"382","author":"Ladhani","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.08.031_b0325","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1016\/j.vaccine.2006.03.091","article-title":"Neisseria meningitidis group B correlates of protection and assay standardization\u2013international meeting report Emory University, Atlanta, Georgia, United States, 16\u201317 March 2005","volume":"24","author":"Borrow","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.08.031_b0330","doi-asserted-by":"crossref","first-page":"19490","DOI":"10.1073\/pnas.1013758107","article-title":"Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines","volume":"107","author":"Donnelly","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2020.08.031_b0335","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1016\/j.vaccine.2010.12.075","article-title":"Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and Neisserial heparin binding antigen","volume":"29","author":"Vu","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.08.031_b0340","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1016\/j.vaccine.2017.06.020","article-title":"The role of anti-NHba antibody in bactericidal activity elicited by the meningococcal serogroup B vaccine, MenB-4C","volume":"35","author":"Partridge","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.08.031_b0345","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1016\/j.vaccine.2013.08.006","article-title":"Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage","volume":"31","author":"Frosi","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.08.031_b0350","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1128\/IAI.00411-07","article-title":"Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis","volume":"75","author":"Weynants","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.08.031_b0355","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1208\/s12248-016-9979-x","article-title":"The dual role lipids of the lipoproteins in Trumenba, a self-adjuvanting vaccine against meningococcal meningitis B disease","volume":"18","author":"Luo","year":"2016","journal-title":"AAPS J"},{"key":"10.1016\/j.vaccine.2020.08.031_b0360","doi-asserted-by":"crossref","unstructured":"Feavers IM, Fox AJ, Gray S, Jones DM, Maiden MC. Antigenic diversity of meningococcal outer membrane protein PorA has implications for epidemiological analysis and vaccine design. Clin Diagn Lab Immunol 1996;3:444-50.","DOI":"10.1128\/cdli.3.4.444-450.1996"},{"key":"10.1016\/j.vaccine.2020.08.031_b0365","doi-asserted-by":"crossref","unstructured":"McNeil LK, Donald RGK, Gribenko A, French R, Lambert N, Harris SL, et al. Predicting the susceptibility of meningococcal serogroup B isolates to bactericidal antibodies elicited by bivalent rLP2086, a novel prophylactic vaccine. MBio 2018;9:e00036-18.","DOI":"10.1128\/mBio.00036-18"},{"key":"10.1016\/j.vaccine.2020.08.031_b0370","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41541-019-0154-0","article-title":"Selection of diverse strains to assess broad coverage of the bivalent FHbp meningococcal B vaccine","volume":"5","author":"Harris","year":"2020","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2020.08.031_b0375","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/14760584.2018.1483726","article-title":"From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine","volume":"17","author":"Perez","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2020.08.031_b0380","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1056\/NEJMoa1614474","article-title":"A bivalent meningococcal B vaccine in adolescents and young adults","volume":"377","author":"Ostergaard","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.08.031_b0385","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/INF.0000000000001399","article-title":"Neisseria meningitidis serogroup B vaccine, bivalent rLP2086, induces broad serum bactericidal activity against diverse invasive disease strains including outbreak strains","volume":"36","author":"Harris","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2020.08.031_b0390","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00121-17","article-title":"Breadth and duration of meningococcal serum bactericidal activity in healthcare workers and microbiologists immunized with the MenB-FHbp vaccine","volume":"24","author":"Lujan","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2020.08.031_b0395","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.vaccine.2017.01.066","article-title":"Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France","volume":"35","author":"Taha","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.08.031_b0400","doi-asserted-by":"crossref","first-page":"6867","DOI":"10.1016\/j.vaccine.2018.05.081","article-title":"The bivalent factor H binding protein meningococcal serogroup B vaccine elicits bactericidal antibodies against representative non-serogroup B meningococci","volume":"36","author":"Harris","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.08.031_b0405","unstructured":"ClinicalTrials.gov. A study to describe the immunogenicity, safety, and tolerability of Neisseria meningitidis serogroup B bivalent recombinant lipoprotein 2086 vaccine (bivalent rLP2086) in healthy subjects aged \u226524 months to <10 years (NCT02531698); 2018 [accessed April 29, 2020]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02531698."},{"key":"10.1016\/j.vaccine.2020.08.031_b0410","unstructured":"ClinicalTrials.gov. Immunogenicity, safety and tolerability of a Neisseria meningitidis serogroup B bivalent recominant lipoprotein 2086 vaccine (bivalent rLP2086) in healthy toddlers (NCT02534935); 2018 [accessed June 25, 2020]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02534935."},{"issue":"3","key":"10.1016\/j.vaccine.2020.08.031_b0415","doi-asserted-by":"crossref","first-page":"e01231-19","DOI":"10.1128\/mBio.01231-19","article-title":"A meningococcal outer membrane vesicle vaccine with overexpressed mutant FHbp elicits higher protective antibody responses in infant rhesus macaques than a licensed serogroup B vaccine","volume":"10","author":"Beernink","year":"2019","journal-title":"MBio"},{"key":"10.1016\/j.vaccine.2020.08.031_b0420","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.1016\/j.vaccine.2011.04.095","article-title":"Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys","volume":"29","author":"Koeberling","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.08.031_b0425","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.88907","article-title":"Enhanced protective antibody to a mutant meningococcal factor H-binding protein with low-factor H binding","volume":"1","author":"Granoff","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.vaccine.2020.08.031_b0430","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/s41467-018-03146-7","article-title":"Structure-based design of chimeric antigens for multivalent protein vaccines","volume":"9","author":"Hollingshead","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2020.08.031_b0435","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1098\/rsif.2007.0236","article-title":"Vaccine-induced pathogen strain replacement: what are the mechanisms?","volume":"5","author":"Martcheva","year":"2008","journal-title":"J R Soc Interface"},{"key":"10.1016\/j.vaccine.2020.08.031_b0440","doi-asserted-by":"crossref","first-page":"e1001517","DOI":"10.1371\/journal.pmed.1001517","article-title":"Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites","volume":"10","author":"Feikin","year":"2013","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2020.08.031_b0445","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3201\/eid2503.181574","article-title":"University-based outbreaks of meningococcal disease caused by serogroup B, United States, 2013-2018","volume":"25","author":"Soeters","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2020.08.031_b0450","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S1473-3099(17)30301-8","article-title":"Impact of MenAfriVac in nine countries of the African meningitis belt, 2010\u201315: an analysis of surveillance data","volume":"17","author":"Trotter","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2020.08.031_b0455","unstructured":"Public Health England. Invasive meningococcal disease in England: annual report for 2017 to 2018 supplementary data tables; 2018, [accessed August 16, 2019]. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/752085\/Laboratory_confirmed_cases_of_IMD_England_data_tables_2017to2018.pdf"},{"key":"10.1016\/j.vaccine.2020.08.031_b0460","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1473-3099(14)70806-0","article-title":"Epidemiology of invasive meningococcal disease in the Netherlands, 1960\u20132012: an analysis of national surveillance data","volume":"14","author":"Bijlsma","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2020.08.031_b0465","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40121-019-0254-1","article-title":"Epidemiologic trends, global shifts in meningococcal vaccination guidelines, and data supporting the use of MenACWY-TT vaccine: a review","volume":"8","author":"Presa","year":"2019","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.vaccine.2020.08.031_b0470","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00430-017-0524-z","article-title":"Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance","volume":"207","author":"Dorji","year":"2018","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2020.08.031_b0475","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065043","article-title":"An analysis of the sequence variability of meningococcal fHbp, NadA and NHBA over a 50-year period in the Netherlands","volume":"8","author":"Bambini","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.08.031_b0480","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1097\/INF.0b013e31829aa63b","article-title":"A multi-country evaluation of Neisseria meningitidis serogroup B factor H-binding proteins and implications for vaccine coverage in different age groups","volume":"32","author":"Hoiseth","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2020.08.031_b0485","unstructured":"Abad R, Garcia C, Navarro C, Vazquez JA. Genetic variability of the meningococcal serogroup B vaccine antigens: analysis of 2015-2016 invasive MenB strains in Spain. In: 15th European Meningococcal and Haemophilus Disease Society Congress; 2019 May 27-30; Lisbon, Portugal."},{"key":"10.1016\/j.vaccine.2020.08.031_b0490","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1017\/S0950268800066449","article-title":"The Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica","volume":"99","author":"Cartwright","year":"1987","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2020.08.031_b0495","doi-asserted-by":"crossref","first-page":"B64","DOI":"10.1016\/j.vaccine.2009.04.061","article-title":"Meningococcal carriage and disease\u2013population biology and evolution","volume":"27","author":"Caugant","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.08.031_b0500","doi-asserted-by":"crossref","first-page":"B20","DOI":"10.1016\/j.vaccine.2009.04.067","article-title":"Meningococcal C conjugate vaccine: the experience in England and Wales","volume":"27","author":"Campbell","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.08.031_b0505","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/527401","article-title":"Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity","volume":"197","author":"Maiden","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.08.031_b0510","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1056\/NEJMoa1900236","article-title":"Meningococcal B vaccine and meningococcal carriage in adolescents in Australia","volume":"382","author":"Marshall","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.08.031_b0515","article-title":"Impact of meningococcal B (4CMenB) vaccine on pharyngeal Neisseria meningitidis carriage density and persistence in adolescents","author":"McMillan","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2020.08.031_b0520","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/cid\/cix091","article-title":"Meningococcal carriage evaluation in response to a serogroup B meningococcal disease outbreak and mass vaccination campaign at a college-Rhode Island, 2015\u20132016","volume":"64","author":"Soeters","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2020.08.031_b0525","doi-asserted-by":"crossref","unstructured":"McNamara LA, Thomas JD, MacNeil J, Chang HY, Day M, Fisher E, et al. Meningococcal carriage following a vaccination campaign with MenB-4C and MenB-FHbp in response to a university serogroup B meningococcal disease outbreak-Oregon, 2015-2016. J Infect Dis 2017;216:1130-40.","DOI":"10.1093\/infdis\/jix446"},{"key":"10.1016\/j.vaccine.2020.08.031_b0530","unstructured":"Evaluating the effect of immunisation with group B meningococcal vaccines on meningococcal carriage (EudraCT number: 2017-004609-42), [accessed July 17, 2020] https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004609-42\/GB."},{"key":"10.1016\/j.vaccine.2020.08.031_b0535","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1016\/j.vaccine.2010.11.072","article-title":"Distribution of factor H binding protein beyond serogroup B: variation among five serogroups of invasive Neisseria meningitidis in South Africa","volume":"29","author":"Mothibeli","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.08.031_b0540","doi-asserted-by":"crossref","unstructured":"Jolley KA, Bray JE, Maiden MCJ. Open-access bacterial population genomics: BIGSdb software, the PubMLST.org website and their applications. Wellcome Open Res 2018;3:124. https:\/\/dx.doi.org\/10.12688\/wellcomeopenres.14826.1.","DOI":"10.12688\/wellcomeopenres.14826.1"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20310720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20310720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:48:54Z","timestamp":1759402134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20310720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":108,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0264410X20310720"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.08.031","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Broad vaccine protection against Neisseria meningitidis using factor H binding protein","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.08.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2020 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}